Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
KMZ Holdings is a private healthcare technology company developing non-invasive diagnostic systems under the Zeptronic Diagnostics brand. The company describes its core product as a hand-held probe connected to a proprietary cloud-based analytics platform that generates rapid whole-body diagnostic reports. Public materials indicate applications across infectious disease and broader diagnostic screening, including COVID-19, HIV, hepatitis, and routine chemistry-style assessments. KMZ Holdings has also publicly discussed a related "Femto Water" product and broader femto-particle technology concepts, though the company's clearest healthcare positioning is in diagnostics. Overall, the business appears to be an early-stage medical diagnostics and device/software platform company rather than a therapeutics developer.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on KMZ Holdings.